Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: NSCI
Market: AIM
52-week High/Low: 85.00p / 50.00p
Sector: Pharma & Biotech
Market Cap: 28.73M
Phone: +44 (0)20 3514 1800
Address: 30 St Mary Axe, London EC3A 8BF.
Website: netscientific.net
Netscientific PLC

Netscientific PLC

NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society.

NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.

NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.

Netscientific PLC

netscientific.net

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Netscientific PLC


Netscientific PLC Snapshot

NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society.

NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.

NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.

For further information please click here

 

François Martelet, Chief Executive Officer, joined NetScientific in 2015.

He brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. He has broad experience in both large and small companies, deep knowledge of commercialisation and has proven managerial capabilities

Previously, François served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.

Prior to this, François served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly.

François gained a Doctorate in Medicine and a Master's Degree in Business from Dijon University, and holds a Degree in Legal Medicine from R. Descartes University School of Medicine, Paris. He is also a graduate of the Advanced General Management Program at INSEAD.

François Martelet's awards include the Pasteur Institute medal (1989) and the Knight of the French National Order Merit (2011).

Ian Postlethwaite, Chief Financial Officer, joined NetScientific in June 2016.

He brings over 14 years of biopharma experience and a proven track record of driving revenue growth and funding development programs. He has broad experience in both private and public companies; from start-ups to multi-nationals.

He was previously an Executive Director on the board of Allergy Therapeutics Plc. He joined Allergy in April 2002 as Finance Director whilst it was private company, initially performing a financial turnaround and then listing it two years later in 2004 on the AIM of the London Stock Exchange. Revenue increased from £12 to c.£49m over his tenure and he raised £107m through equity issues and €40m through debt finance to fund over 15 clinical studies.

Prior to this he worked for Ellerman Investments (1997-2002), a UK private equity house, undertaking the roles of Chief Executive Officer with AFS, which was one of the largest independent finance houses in the UK, raising over £400m in debt finance, and Finance Director with a number of successful start-up technology companies. Previously he held senior finance positions with Ericsson and Philips Electronics.

He is also a non-executive director and Deputy Chairman of Shoreham Port. He is a Fellow of the Chartered Association of Certified Accountants and has a BSc (Hons) in Geological Sciences from Aston University.

Ernest Schneider, Commercial-Legal Director, Company Secretary and Group General Counsel, joined NetScientific in August 2010. He is a solicitor, patent & trade mark attorney and accredited mediator.

He was a partner with two large London law firms after which he established a successful international niche intellectual property firm.  Ernest has negotiated and drafted numerous technology cross-licence, joint venture and M&A agreements.  He has masterminded, put in place and maintained a worldwide licensing programme with hundreds of patent licence agreements. He has enforced, defended and challenged intellectual property rights around the world, conducting litigation, arbitration and mediation in most countries in Europe and in the USA, Canada, Hong Kong, Australia and New Zealand. Interwoven with his legal practice, Ernest has held executive and non-executive directorships and chairmanships in industry. He also has personal entrepreneurial experience, having set up and shut down a couple of business ventures of his own.

Ernest grew up in Lancaster, Florida and Luxembourg where he took his baccalauréat in sciences. He obtained his first degree in economics from Lancaster University Management School and then read law and postgraduate EU law at Leeds Business School.  He is fluent in French, German and Lëtzebuergesch, has fluent but colloquial Hungarian and useful intermediate Spanish.

Meera Shah - Financial Controller

A Chartered Accountant with expertise in financial management, evaluation and analysis with a commercial focus – including setting up her own commercial venture. A Bristol University graduate qualifying as an accountant with Littlejohn Frazer and post qualification experience with PricewaterhouseCoopers, Meera has gained her commercial experience at T-Mobile, Marks and Spencer before taking on the role of Financial Controller at Merrill Legal Solutions.

To see more of the team click here

NetScientific plc

30 St Mary Axe

London EC3A 8BF

Tel: +44 20 3514 1800

[email protected]

 

Press Contact:
Consilium Strategic Communications
Mary-Jane Elliott 
Tel: +44 (0)20 3709 5700
[email protected]

Netscientific PLC Timeline

Columns Including NSCI

VIEW ALL

Market Reports Including NSCI

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.